BioAI Health

BioAI Health is a private, pre-revenue AI-driven biotech company developing the PredictX platform, a multimodal causal AI system designed to analyze complex biomedical data including histopathology, spatial transcriptomics, and single-cell RNA sequencing. The company operates a hybrid business model, offering AI biomarker discovery services, data sourcing, and computational pathology expertise to biopharma partners, positioning itself as an enabler for faster, more precise drug development and diagnostics. With a leadership team boasting decades of industry experience, BioAI aims to translate AI insights into novel digital diagnostic assays and therapeutic targets, primarily in oncology, starting with lung cancer.

PredictX Platform: A multimodal causal AI system integrating in-silico phenotype projection, deep learning, and probabilistic programming to analyze digital pathology, spatial transcriptomics, and single-cell RNA-seq data for digital biomarker development and drug target discovery.

BioAI operates in a highly competitive field with numerous players like PathAI, Tempus, Recursion, and Owkin, as well as tech giants (Google, NVIDIA). Its claimed differentiation lies in its specific focus on multimodal causal AI and in-silico phenotype projection, combined with deep translational science expertise, aiming to provide more biologically interpretable insights than correlation-based models.